Author | Ennes-Vidal, Vítor | |
Author | Santos, André Luis Souza dos | |
Author | Branquinha, Marta Helena | |
Author | d’Avila-Levy, Claudia Masini | |
Access date | 2022-03-27T14:05:57Z | |
Available date | 2022-03-27T14:05:57Z | |
Document date | 2022 | |
Citation | ENNES-VIDAL, Vítor et al. Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 117, e220017, p. 1-5, 2022. | pt_BR |
ISSN | 0074-0206 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/51899 | |
Language | eng | pt_BR |
Publisher | Fiocruz/IOC | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Doença de Chagas | pt_BR |
Subject in Portuguese | Leishmaniose | pt_BR |
Subject in Portuguese | Calpaína | pt_BR |
Subject in Portuguese | Estratégia de reaproveitamento | pt_BR |
Title | Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors | pt_BR |
Type | Article | pt_BR |
DOI | 10.1590/0074-02760220017 | |
Abstract | The treatment for tropical neglected diseases, such as Chagas disease (CD) and leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures due to the parasite resistance. Consequently, there is urgency for the development of new therapeutic options to treat such diseases. Since peptidases from these parasites are responsible for crucial functions in their biology, these molecules have been explored as alternative targets. In this context, a myriad of proteolytic inhibitors has been developed against calciumdependent cysteine-type peptidases, collectively called calpains, which are implicated in several human pathophysiological diseases. These molecules are highly expanded in the genome of trypanosomatids and they have been reported participating in several parasite biological processes. In the present perspective, we discuss our almost two decades of experience employing the calpain inhibitors as an interesting shortcut to a possible repurpose strategy to treat CD and leishmaniasis. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Estudos Integrados em Protozoologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Química. Programa de Pós-Graduação em Bioquímica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Estudos Integrados em Protozoologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Repurposing strategy | pt_BR |
Subject | Calpains | pt_BR |
Subject | Chagas disease | pt_BR |
Subject | Leishmaniasis | pt_BR |
e-ISSN | 1678-8060 | |